NCT06484920
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 7 with changes below. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Loss of research support Show 7 more changesShow less
- Primary endpoint(s) modified
- Final enrollment: 1 participants, 4% of the 24 planned
- Results posted: Nov 17, 2026
- Eligibility criteria expanded, about 44 words
- Primary completion date changed from estimate of Dec 2027 to Jun 3, 2025
- Secondary endpoints revised (3)
- Site details revised at 2 of 2 sites
- Minor Site contacts updated at 1 of 2 sitesv6
- Notable Eligibility criteria revised
- Site contacts updated at 2 of 2 sites
- Minor Start date changed from estimate of Oct 2024 to Nov 18, 2024
- Site contacts updated at 1 of 2 sites
- Notable Start date: Aug 2024 to Oct 2024
- Study completion date: Dec 2030 to Sep 2029
- Site contacts updated at 2 of 2 sites
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Jul 2024 to Aug 2024
- Site details revised at 2 of 2 sites
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Safety: Percentage of Patients With Treatment-Related Adverse Events
Timeframe: On treatment date to end of study (up to 1 month)
Secondary (3)
Overall Response Rate (Percentage of Patients With Complete Response or Partial Response)
Complete Remission Rate
Change in Patient Derived Myeloid-derived Suppressor Cells (MDSC)
Arms and interventions
ATRA and PembrolizumabExperimental
Patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 ATRA orally for 3 days surrounding each of the first four infusions of pembrolizumab (day -1, day 0, day +1).
Drugs: ATRA, Pembrolizumab
Sites
2 sites in 1 country